Plain-English translation of NCT06914674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Neoplasms research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing tamoxifen, a medication that blocks estrogen in the body, to see if it can help people with advanced solid pseudopapillary tumors of the pancreas (a rare type of pancreatic cancer). Some of these tumors have receptors that respond to hormones like estrogen, which may help the medication work. This study will evaluate whether the medication is safe and effective for people whose cancer has spread, come back after treatment, or cannot be removed by surgery.
People with advanced cases of this rare pancreatic tumor currently have very few treatment options beyond surgery. Case reports suggest this medication might help patients whose tumors respond to hormone-blocking therapy, but it hasn't been formally tested in a clinical trial.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth twice daily and come in for regular study visits to check how you're doing and monitor your tumor. Depending on your situation, you may also receive other standard treatments like chemotherapy, radiation, or surgery as recommended by your medical team. The study will track how well the medication works and watch for any side effects over time.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~30 participants
Started
March 2025
Primary completion
February 2027
Age range
14 Years – 80 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huanyu Xia MD
Shanghai Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.